Supernus Pharmaceuticals, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported revenue was USD 143.64 million compared to USD 153.76 million a year ago. Net income was USD 0.124 million compared to USD 16.95 million a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.77 USD | -0.36% | -3.38% | -4.04% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.04% | 1.53B | |
+9.28% | 8.74B | |
-15.14% | 4.94B | |
+50.73% | 4.7B | |
+4.36% | 3.98B | |
-26.13% | 2.28B | |
+12.07% | 2.28B | |
+16.45% | 2.14B | |
-33.59% | 2.12B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- SUPN Stock
- News Supernus Pharmaceuticals, Inc.
- Supernus Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024